Background: The optimal treatment for hepatitis C patients unresponsive to interferon is unclear. Highdose induction interferon may enhance early viral clearance, whilst ribavirin reduces relapse; in combination, they may improve sustained virological response rates. Aim: To compare the efficacy and safety of re-treatment with interferon induction, with or without ribavirin, in interferon non-responders. Methods: We randomized 218 biochemical interferon non-responders to 10 MU interferon a2b daily for 4 weeks, followed by 5 MU thrice weekly for 48 weeks plus ribavirin (II + R), or to the same interferon
INTRODUCTION
The failure to eradicate chronic hepatitis C virus (HCV) infection following anti-viral therapy presents a substantial clinical challenge. Viral eradication is defined as undetectable serum HCV RNA, determined by a sensitive assay, 6 months following the end of treatment, and is designated a sustained virological response (SVR). Prior to the widespread use of nucleic acid testing for viral RNA, the normalization of serum alanine aminotransferase (ALT) was commonly used to indicate treatment outcome, and was described as a biochemical response. With regard to treatment outcome, interferon monotherapy is effective in less than 20% of previously untreated patients. The combination of interferon plus ribavirin improves the SVR to 40%, and recently reported trials of pegylated interferon plus ribavirin have demonstrated an overall SVR in approximately 55% of previously untreated patients. [1] [2] [3] [4] Similarly, combination therapy achieves significantly better results in patients who relapse following interferon monotherapy, compared with re-treatment with interferon alone. 5 Despite these advances, treatment for chronic HCV infection remains unsatisfactory for patients unresponsive to interferon alone or to standard combination therapy. Viral kinetic studies have shown that early or phase 1 clearance of circulating virus is rapid, interferon mediated and represents the blockade of viral production or release from infected hepatocytes. 6, 7 Phase 1 clearance is interferon dose dependent; the greatest effect is seen with 10 MU daily with a blocking efficacy of 95%. 6 Ribavirin does not alter early viral clearance, but increases the end-of-treatment response and prevents relapse, perhaps by enhancing the immune clearance of infected hepatocytes. Therefore, the administration of high-dose interferon during the first weeks of therapy, so-called induction dosing, may be an effective treatment strategy, although the proportion of patients who achieve an SVR following induction dosing remains unclear. An SVR following re-treatment with standard-dose interferon and ribavirin occurs in no more than 15% of patients unresponsive to an initial course of interferon. [8] [9] [10] [11] There have been no large studies of high-dose daily interferon therapy in interferon non-responding patients. Therefore, we compared the efficacy and tolerability of interferon induction dosing, with or without ribavirin, in a large cohort of HCV-infected patients with a previous biochemical non-response to interferon monotherapy.
PATIENTS AND METHODS

Patient selection
Patients with chronic HCV infection, aged between 18 and 55 years, who had not responded to an initial course of interferon monotherapy, were included. All patients had abnormal serum ALT values prior to original therapy with either interferon a2b or a2a given thrice weekly. The majority of patients (72%) received between 3 and 6 months of interferon monotherapy; 28% were treated for 6-12 months. We defined nonresponse biochemically by a failure to normalize serum ALT levels during a minimum of 12 weeks of interferon treatment. At least two abnormal ALT values were documented during the initial treatment course and one was in the last 4 weeks of therapy. Patients who showed normalized serum ALT levels at any time during the initial interferon course and subsequently developed abnormal ALT values during therapy ('breakthrough') or after the end of treatment (relapse) were not included.
Prior to entry into the current study, all patients had detectable serum HCV RNA by polymerase chain reaction, abnormal serum ALT values and a liver biopsy performed within the 24 months prior to study entry. A single liver pathologist (PB) evaluated all liver biopsies according to the Ishak score.
12 Study investigators recruited subjects from hospital liver or hepatitis clinics. The institutional review boards or human research and ethics committees of all participating hospitals approved the study protocol. Subjects with chronic liver disease not due to HCV infection, decompensated liver disease, insulin-dependent diabetes, human immunodeficiency virus infection, significant cardiovascular or psychiatric disease, excessive alcohol consumption and inability to utilize adequate contraception were excluded.
Study design
The study was randomized, double-blind and placebocontrolled for ribavirin. After giving written informed consent, patients were randomly allocated to one of two treatment arms through a concealed process using a computer-generated block randomization schedule at a central location. Following an interval of at least 6 months after their previous interferon monotherapy course, all patients received recombinant interferon a2b (Intron-A, Schering Plough), 10 MU daily for 4 weeks, followed by 5 MU thrice weekly for 48 weeks, either with ribavirin (induction interferon + ribavirin group, II + R) or matching placebo (induction interferon + placebo group, II + P). Ribavirin (Rebetol, Schering Plough) was administered at a dose of 1 or 1.2 g/day (for a body weight of £ 75 kg or > 75 kg, respectively) for 52 weeks. Dose modification was allowed for changes in serum haemoglobin, white cell and platelet counts; however, haematopoietic growth factors were not used. Patients who experienced intolerable side-effects during the 4 weeks of induction therapy, other than adverse events related to the laboratory variables described, were discontinued from the study rather than undergoing dose reduction. Patients with detectable HCV RNA at study week 12 were defined as non-responders and the study drug was discontinued. Medication compliance was monitored by ribavirin pill count and the return of used interferon vials. Source data from individual study sites were monitored at scheduled visits throughout the study.
Detection of HCV antibody, genotype and viral load
Specific antibodies to HCV were determined by reactivity in two independent second-generation enzyme immunoassays (Abbott Diagnostics, Chicago, IL, USA and Murex Diagnostics, Dartford, UK). HCV RNA was detected by polymerase chain reaction using the commercial Roche AMPLICOR HCV test (Roche Diagnostic Systems, Branchburg, NJ, USA). Polymerase chain reaction-positive samples were quantified using the Quantiplex HCV RNA (branched DNA) assay (Chiron, Emeryville, CA, USA). Viral load was reported as million equivalents per millilitre (MEq/mL) (detection limit, 0.2 MEq/mL). The HCV genotype was determined using a line-probe assay (INNO-LiPA, Innogenetics, Belgium).
End-points and statistical analysis
The study was analysed by intention-to-treat, and all patients who were randomized and received at least one dose of study drug were included in the efficacy and safety analyses. Quantitative serum HCV RNA was performed at baseline and at weeks 2, 4 and 6. Qualitative serum HCV RNA and serum ALT were measured at week 12, at the end of treatment (week 52) and at the end of follow-up (week 76). The primary outcome measure was the HCV RNA status measured by qualitative polymerase chain reaction at week 76. A chi-squared test for proportions was used to estimate the number of patients required for the study to achieve a power of 80% at a significance level of 0.05. From the data available at the time of protocol development, we estimated that an SVR would occur in 5% of interferontreated patients and in 20% receiving combination therapy; hence, 75 patients per treatment arm were required. Allowing for a 30% drop-out/non-evaluable rate, 110 patients were required in each treatment arm. Baseline demographics were compared using the chi-squared test for discrete variables and Wilcoxon's rank sum test for continuous variables. Comparisons of treatment response were made by the chi-squared test. Possible associations between host and viral factors and sustained response were examined by logistic regression analysis and the results were reported as odds ratios (OR) with 95% confidence intervals (CI).
RESULTS
Patient characteristics
Study enrolment began in December 1997 and was completed by December 1998. All patients completed the study protocol by August 2000. A total of 247 patients were screened; however, 25 did not meet the entry criteria and four met the entry criteria but were not randomized. These 29 patients were excluded from further analysis. Thus 218 patients were randomized, 111 to the II + R group and 107 to the II + P group. The baseline characteristics of the patients are summarized in Table 1 and the treatment outcomes are given in Table 2 and Figures 1 and 2. Compliance with study medication was > 90%.
Virological response
HCV RNA was detected at week 12 in 28 patients (25%) in the II + R group and in 63 patients (59%) in the II + P group (P < 0.001); these viraemic patients were withdrawn from further treatment ( Table 2) . At the end of treatment, HCV RNA was undetectable in significantly more patients in the II + R group (49/111, 44%) than in those in the II + P group (27/107, 25%) (P ¼ 0.006) (Figure 1 ). At the end of follow-up (week 76), serum HCV RNA was undetectable in 39% (95% CI, 30-48%) of patients in the II + R group, compared with 16% (95% CI, 9-23%) in the II + P group (P < 0.002). Two patients in the II + R group with undetectable serum HCV RNA at week 52 did not have a sample available at week 76 and were regarded as treatment failures for the intention-to-treat analysis, although both were subsequently found to have undetectable serum HCV RNA on samples analysed 3 and 24 months following week 76. We then analysed the virological response by genotype. In subjects with HCV genotype 1 or 4, an SVR occurred in 27% (20/74) of patients in the II + R group, compared with 9% (7/78) of patients in the II + P group (P ¼ 0.006). In subjects with genotype 2 or 3, an SVR was significantly more common in patients in the II + R group (67%, 25/37) than in those in the II + P group (34%, 10/29) (P ¼ 0.014) (Figure 2 ).
Biochemical response
At the end of treatment, serum ALT was normal in 42 patients in the II + R group (38%), compared with 18 patients in the II + P group (17%) (P < 0.001). By week 76, serum ALT was normal in 39 patients in the II + R group (35%), compared with 14 patients in the II + P group (13%) (P ¼ 0.0001). The II + R group had a mean decrease in ALT of 81 U/L (52% reduction from baseline), compared with 41 U/L (14% reduction from baseline) in the II + P group (P < 0.001). Comparable differences in ALT normalization were observed at week 76. 24 (22) 26 (24) ALT, alanine aminotransferase; HCV, hepatitis C virus; II + P, induction interferon + placebo; II + R, induction interferon + ribavirin. 
Factors associated with treatment response
We examined the treatment regimen, HCV genotype, baseline serum ALT, pre-treatment viral load, histological inflammation and fibrosis score, age, gender, ethnicity, duration of infection, route of exposure and body mass index for an association with SVR. Treatment with induction interferon plus ribavirin (P ¼ 0.0002) and genotype 1 or 4 (P < 0.0001) were associated with SVR by univariate analysis. Patients with baseline serum ALT in the highest quartile were more likely to respond than patients with lower serum ALT values (P ¼ 0.01). The body mass index approached statistical significance in relation to outcome (P ¼ 0.078). Patients with mild or moderate fibrosis (stages 0-3) responded similarly to those with more advanced fibrosis (stages 4-6). Pre-treatment viral load did not differ between responders and nonresponders. Although sustained responders in the II + R group were significantly less likely to have a measurable viral load during the first 6 weeks of therapy compared with those in the II + P group (7% vs. 29%, respectively; P < 0.001), both groups demonstrated a similar reduction in viral load. No other host or viral factor was associated with outcome. Multiple logistic regression confirmed that treatment regimen, HCV genotype and baseline serum ALT were independent factors associated with a sustained response. Patients in the II + R group were more likely to have an SVR than those in the II + P group (OR, 4.4; 95% CI, 2-9.7). Patients with genotype 1 or 4 were significantly less likely than those with genotype 2 or 3 to achieve a sustained response (OR, 0.16; 95% CI, 0.07-0.36). When divided by quartiles, patients with the highest serum ALT values were more likely to respond than patients in the lowest serum ALT quartile (OR, 5.1; 95% CI, 1.4-17.7). Further sub-group analysis showed that this relationship was valid for patients with genotype 1 or 4 (OR, 7.1; 95% CI, 1.7-29), but not for those with genotype 2 or 3 (OR, 1.4; 95% CI, 0.3-6.3).
Adverse events, dose modification and treatment discontinuation
Adverse events were common in both groups; 'influenza-like symptoms' were reported by 55% in the II + R group and by 50% in the II + P group; headache occurred in 71% and 73% and myalgia in 64% and 56%, respectively. Depression occurred in 23% of the II + R group and in 14% of the II + P group. Haematological changes were common; the mean decrease in serum haemoglobin in the II + R group was 22 g/L, compared with 11 g/L in the II + P group (P ¼ 0.001). The mean decrease in platelets was greater in the II + P group (46 000 · 10 9 /L) than in the II + R group (29 000 · 10 9 /L) (P ¼ 0.015).
The study drug was permanently discontinued in 17 patients (15%) in the II + R group and in 11 patients Subjects with genotype (GT) 2 or 3 and those treated with induction interferon + ribavirin (II + R) were significantly more likely to achieve a sustained response. Genotype 1 or 4 patients were significantly more likely to respond to II + R (P ¼ 0.006).
(10%) in the II + P group. Severe neutropenia leading to drug discontinuation during the induction period occurred in three patients in the II + R group and in two patients in the II + P group. During the induction period, dose reduction for intolerable symptoms, such as nausea, irritability and headache, was not allowed and the drug was discontinued for these reasons in 10 patients (9%) in the II + R group and in five patients (5%) in the II + P group. Other reasons for drug discontinuation in the II + R group were cholecystitis in one patient (week 1), rash or urticaria in two patients (both week 1) and emotional lability in one patient (week 17). Other reasons for drug discontinuation in the II + P group were tonsillitis in one patient (week 2), hypothyroidism in two patients (weeks 12 and 17) and emotional lability in one patient (week 30). Dose reduction in the II + R group was necessary in one patient with anaemia at week 3 and one with blurred vision at week 8, and in the II + P group in one patient with thrombocytopenia at week 3.
DISCUSSION
This is the largest reported randomized controlled trial of induction dose interferon combined with ribavirin in interferon non-responders. We demonstrated that 39% of biochemical non-responders to interferon monotherapy achieved an SVR with this regimen. The addition of ribavirin to the induction regimen was critical, as the SVR rate to induction interferon alone was only 16%. Ribavirin significantly enhanced the end-of-treatment response rate from 25% in the II + P arm to 44% in the II + R group, in addition to decreasing the relapse rate as reported previously.
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The regimen was well tolerated and relatively few patients were withdrawn during the induction period because of intolerable side-effects related to the study drugs.
As in the majority of previous re-treatment studies of interferon non-responders, we defined non-response biochemically, by abnormal serum ALT, rather than virologically, by detectable HCV RNA. Although all patients had documented serum HCV RNA at entry into the current study, data on detectable viraemia at the end of the previous interferon regimen were not available as nucleic acid testing for HCV RNA detection was not widely available at that time. Thus, a proportion of patients with abnormal serum ALT following 12 weeks or more of interferon may have had undetectable serum HCV RNA. Approximately 15-25% of interferon-treated patients at the end of 12-24 weeks of treatment have abnormal serum ALT but undetectable HCV RNA. 13, 14 Our definition of nonresponse could potentially overestimate the treatment effect for non-responding patients by including a small proportion of relapsed patients in addition to true primary non-responders, although randomization should have equalized this potential source of bias. In addition, re-treatment of interferon relapsers with interferon alone results in a substantial end-of-treatment response, up to 47% in one large study. 5 The 44%
end-of-treatment response in the II + R group, compared with 25% in the group re-treated with interferon alone (Figure 1) , suggests that the superior SVR rate in the II + R group is unlikely to be due to the inclusion of a large proportion of relapsed patients. Although we did not include a treatment arm with standard-dose interferon plus ribavirin, three recent meta-analyses and a systematic review have examined the efficacy of re-treatment with interferon plus ribavirin in patients unresponsive to interferon monotherapy, generally defined by a biochemical rather than virological response. In the first meta-analysis of nine randomized controlled trials comprising 789 patients, the pooled SVR following 6 months of standard combination therapy was 13%, with an odds ratio of 4.9 in favour of combination therapy. 8 A second meta-analysis examined 12 randomized controlled trials with 941 patients, and the pooled SVR was 14% (95% CI, 11-17%) in patients re-treated with combination therapy, compared with 2% for interferon alone. 9 A third meta-analysis analysed 10 randomized controlled trials with 1728 patients, and determined a pooled SVR of 13% (95% CI, 13-16%). 10 A systematic review of randomized trials of interferon, with or without ribavirin, suggested that approximately 15% of non-responders obtained an SVR with combination therapy. 11 Thus, the cumulative evidence suggests that re-treatment with interferon in standard doses (3-6 MU thrice weekly) plus ribavirin benefits no more than 15% of interferon non-responders. The rationale for induction dosing comes from studies such as that of Neumann et al., which showed a more rapid decline in viral load in 23 previously untreated genotype 1 patients given 10 MU interferon a2b daily compared with 5 MU over 14 days. 6 A recent study of high-dose daily interferon for 6 weeks, followed by combination interferon plus ribavirin for 42 weeks, suggested that phase 2 kinetics may also correlate with SVR, which was 50% in a cohort of 28 previously untreated HCV genotype 1 patients. 15 Ferenci et al.
showed that a high-dose induction regimen (10 MU interferon a2b daily for 2 weeks followed by 10 MU every other day for 12 weeks) plus ribavirin achieved a 44% SVR in previously untreated genotype 1 patients, compared with a 28% sustained response following a lower dose induction regimen (5 MU). 16 Interestingly, in that study, there was no advantage for high-dose induction compared with lower dose therapy in previously untreated patients with genotype 3a.
Few studies have examined high-dose interferon induction regimens in patients unresponsive to previous anti-viral therapy. Bekkering et al. administered 10 MU interferon daily for 14 days to 11 interferon monotherapy non-responders, and identified a greater decrease in viral load in sustained responders than in non-responders. 17 In a recent pilot study, Malik et al.
randomized 25 virological non-responders to interferon monotherapy to either 10 MU interferon a2b daily for 10 days, followed by 5 MU daily for 74 days and then 5 MU thrice weekly for 24 weeks (36 weeks in total), or to the same regimen plus ribavirin commencing at day 11. 18 An SVR occurred in 33% of the induction + ribavirin arm and in none of the patients receiving induction interferon alone. Our study extends these findings in a larger group and confirms that a regimen of induction interferon plus ribavirin can achieve acceptable SVR rates (Figure 1 ). The greater efficacy of combination therapy was evident early in treatment, as significantly more patients in the II + R group had undetectable HCV RNA at treatment week 12 ( Table 2) . In our study, genotype 1 patients had a similar SVR to the patients studied by Malik et al. 18 We also observed a high SVR in non-responding patients with genotype 2 or 3 ( Figure 2 ). Multivariate analysis confirmed that treatment with induction interferon plus ribavirin and a non-1 genotype were associated with an SVR. Patients with the highest baseline serum ALT were more likely to respond to treatment, and this effect appeared to be restricted to patients with genotype 1. Neumann et al. identified a significant correlation between baseline serum ALT and second-phase kinetics in genotype 1 patients, and suggested that this represented host cytotoxic T-lymphocyte killing of HCV-infected hepatocytes. 6 Other investigators have identified a correlation between pre-treatment ALT and sustained response in chronic HCV infection. 13 A recent study of intra-hepatic HCV RNA demonstrated an inverse correlation between serum ALT and hepatic HCV RNA prior to anti-viral therapy, suggesting that ALT activity reflected an active host immune response. 19 These data are consistent with a previous report correlating HCV-specific intra-hepatic cytotoxic T-lymphocyte activity with serum ALT. 20 Thus, a high serum ALT may have a role in predicting response in interferon monotherapy non-responders with genotype 1. Currently, there are few data on the outcome following pegylated interferon plus ribavirin therapy in interferon or combination therapy non-responders. Buti et al. found a significantly greater log reduction in viral load over 48 h in previously untreated genotype 1 patients administered peginterferon a2b, 3 lg/kg compared with 0.5 lg/kg. By week 12, HCV RNA clearance had occurred in a greater proportion receiving the higher peginterferon dose. 21 In an ongoing study of interferon non-responders treated with peginterferon plus ribavirin, 56% (10/18) had undetectable HCV RNA at treatment week 24, suggesting that the SVR would be lower. 22 Similarly, a report from the lead-in phase of a large study of peginterferon a2a plus ribavirin in biochemical and virological non-responders confirmed an SVR in 20% of 212 patients. 23 In summary, an induction regimen of daily high-dose interferon plus ribavirin for the re-treatment of interferon non-responders provides an acceptable SVR and is well tolerated. Genotype exerts a major influence on outcome, and genotype 1 patients are less likely to respond than those with genotypes 2 or 3. We believe that it is probable that the benefit seen with high-dose induction interferon plus ribavirin will be replicated by standard-or high-dose pegylated interferon plus ribavirin in non-responders to either interferon alone or combination therapy. The high overall SVR following the induction interferon plus ribavirin regimen in our study indicates that previously unresponsive patients can achieve the important clinical goal of viral eradication.
